Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags ZW49

Tag: ZW49

What to Expect at ESMO 2022: Phase 1 Data of...

ADC Review | Editorial Team
Prelinimary results a Phase 1 study of zanidatamab zovodotin (ZW49), an investigational novel bispecific HER2 targeted antibody-drug conjugate being developed by Zymeworks, will be...
Featured Image: London Tower Bridge. Photo Courtesy: 2018 Fotolia

Zymeworks, Regeneron, Boehringer Ingelheim Pharma and Many Others are Betting on...

ADC Review | Editorial Team
Antibody-Drug -Conjugates (ADCs) have the potential to reduce off-target toxicities in patients by limiting the exposure of normal tissues to the payload and broaden...
Featured Image - San Diego, CA at night. Courtesy 2019 Fotolia

Zymeworks Wins Best ADC Platform Technology Award for ZymeLink

Peter Hofland
Zymeworks, a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics including bispecific antibodies and bispecific antibody-drug conjugates across a wide range of therapeutic indications, has won...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X